The Janeway Lab

The Janeway Lab at Dana-Farber Cancer Institute led by @janeway_MD

Focusing on genomics, precision oncology, and pediatric bone sarcomas

[Katie Janeway @janeway_MD]

New work from the @JanewayLab reporting on a pediatric cancer patient cohort sequenced @DanaFarber with 95! different cancer diagnoses. So important to share data to learn about @RareCancer https://t.co/E24bbUE1OB

[Katie Janeway @janeway_MD]

It is the anniversary of our patient partnered osteosarcoma project — https://t.co/cCaK0hGp7i — creating a clinico-genomic database for the research community to drive discovery. Patients enroll online. Consider referring your patients during #childhoodcancerawareness month

[Caralynn @caralynneh]

Awesome getting to see Maeve from @JanewayLab and @AgentsMIB present a poster at #ASCO23!

[Katie Janeway @janeway_MD]

⁦So happy to see work done by Maeve Smart ⁦@JanewayLab⁩ about Covid-19 infection in pediatric cancer patients at #ASCO2023

[Katie Janeway @janeway_MD]

Excited to present on our patient partnered research on osteosarcoma and leiomyosarcoma next month!!

[MIB Agents Osteosarcoma Alliance @AgentsMIB]

Pediatric Cancer Working Group session
#AACR2023 #osteosarcoma
@OSInstitute @janeway_MD @huntsmancancer @DanaFarber #MIBagents #MakeItBetter

[The Janeway Lab @JanewayLab]

We are excited to share our recent publication in
@JCOPO_ASCO, "FGFR Oncogenic Alterations in Sequenced Pediatric Solid and Brain Tumors Suggest FGFR Is a Relevant Molecular Target in Childhood Cancer.” Thank you to all our collaborators and co-authors!

https://t.co/VyqB5tAHjY

[Brad Silberzahn @BradSilberzahn]

“All authors have contributed equally to this manuscript”

[Stacy W. Gray @stacywgray]

86% of pediatric cancer patients w extracranial solid tumors have genomic alterations that potentially impact clinical care. Important somatic sequencing results from the GAIN/iCAT2 study.Beautiful work @AlannaChurch_MD @janeway_MD @JanewayLab et al. https://t.co/90JJpGpBnu

[Boston Children's News & Research @BCH_InTheNews]

A new study published in @NatureMedicine found that 86 percent of extracranial solid tumors in pediatric patients had genomic alterations. Learn more about the findings from lead author Dr. Alanna Church @AlannaChurch_MD in @HealthDayTweets. https://t.co/rqbJ0XFka7.

[Nature Medicine @NatureMedicine]

An interim report from the GAIN/iCat2 study shows that molecular profiling of pediatric solid malignancies clarifies diagnostic classifications and provides opportunities for matched targeted therapy @janeway_MD @JanewayLab @AlannaChurch_MD
https://t.co/SuFi8gr1jN

[Alanna Church, MD @AlannaChurch_MD]

Getting ready for my presentation 👩‍💼this afternoon at 3p ET. Please join us for this free webinar to get to know @AgentsMIB and to hear about how molecular profiling is helping #ChildhoodCancer
The @NatureMedicine paper is available here: https://t.co/4IuoHGJgP5

[The Janeway Lab @JanewayLab]

An incredibly gifted writer, a bright soul, and an ARMS warrior, Kasey Altman. Rest in the sweetest peace.

[Kasey Altman @kaseeedilla]

The new motto

[Katie Janeway @janeway_MD]

Excited #CCDI Molecular characterization initiative of @COGorg now enrolling #sarcoma! Molecular tumor profiling of enrolled patients @nationwidekids is similar DNA and RNA sequencing as our study just published in @NatureMedicine showing clinical benefit:
https://t.co/BslVmPaK7a

[The Janeway Lab @JanewayLab]

This team <3 @JanewayLab @janeway_MD @hycomeau

[Alanna Church, MD @AlannaChurch_MD]

@notSoJunkDNA @NatureMedicine @janeway_MD @AlyaaIbraheemi @SethPinches @bdcrompton @LauraMacconaill @DFBC_PedCare @DanaFarber @BostonChildrens @SamVolchenboum @JanewayLab All of the data is available in the supplement for the manuscript. The fusions in this cohort are DNAJB1::PRKACA in fibrolamellar carcinoma, an entity beautifully described by @DrSolidTumors here: https://t.co/REUVlJ0wll

[Katie Janeway @janeway_MD]

@AlannaChurch_MD @NatureMedicine @AlyaaIbraheemi @SethPinches @bdcrompton @LauraMacconaill @DFBC_PedCare @DanaFarber @BostonChildrens @SamVolchenboum @JanewayLab It has been great working with @AlannaChurch_MD , colleagues from 16 institutions, and patients and families on this report from the GAIN consortium/iCat2 study addressing the clinical impact of targeted NGS in pediatric solid tumors. Collaboration is key for rare cancers!

[Nature Medicine @NatureMedicine]

An interim report from the GAIN/iCat2 study shows that molecular profiling of pediatric solid malignancies clarifies diagnostic classifications and provides opportunities for matched targeted therapy @janeway_MD @JanewayLab, @AlannaChurch_MD
https://t.co/SuFi8gr1jN

[Brendan Reardon @brendan_reardon]

@NatureMedicine @AlannaChurch_MD @janeway_MD @JanewayLab Congratulations @AlannaChurch_MD, @janeway_MD, and all!

[Michael Miller @M_B_Miller]

@AlannaChurch_MD @NatureMedicine @janeway_MD @AlyaaIbraheemi @SethPinches @bdcrompton @LauraMacconaill @DFBC_PedCare @DanaFarber @BostonChildrens @SamVolchenboum @JanewayLab Congratulations, @AlannaChurch_MD and all! Beautiful and important work that showcases the emerging importance of molecular pathology.